Skip to content

An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects

CompletedPhase 1, Phase 2NCT00972907
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

This is an open label study. The study will consist of 1 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine, administered BID to subjects with chronic anal fissure.

Study details

Official title
An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects
Conditions
  • Chronic Anal Fissure
Interventions
  • Drug: Nifedipine coated suppositories
Sponsor
RDD Pharma Ltd
Start date
2009-12
Primary completion
2011-01
Sex
All
Age range
from 18 Years to 65 Years
Results posted
No results posted in this snapshot
Countries
Israel
Total sites listed
2

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Single anal fissure * Signed written informed consent * Male or female subjects 18 to 65 years of age * Has chronic anal fissure defined as history of anal pain at least three days a week for 30 days duration or more * Visible fibers of the internal sphincter were seen at the base of the fissure or if a sentinel pile was present * VAS of \> 35 mm in screening visit * If female, is nonlactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to entry to the study or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice or be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration. Exclusion Criteria: * Known allergy to Nifedipine, polyethylene-glycol, propylene Glycol or silicone * Fissure resulting from inflammatory bowel disease, venereal disease, perianal psoriasis, immunodeficiency syndrome * Anal abscess * Fixed anal stenosis * Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, moderate to severe congestive heart failure, or cardiac valve abnormalities * Type 1 diabetes mellitus * Insulin treated type 2 diabetes mellitus * History of Renal insufficiency * History of Liver insufficiency * Malignant disease within 5 years of screening * Has uncontrolled hypertension (sitting blood pressure \<160/95 mmHg at screening) * History of chronic gastrointestinal disease * History of rectal surgery * History of gastrointestinal surgery * History of HIV, hepatitis B, hepatitis C * In need of chronic use of medication, with the exception of birth control medications * Currently uses medication for acute illness (other than medications for use of treatment/pain relief of anal fissure) * Has used, in the last four weeks, drugs that may affect blood coagulation, such as Aspirin at a dose higher than 500 mg/day , Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine * Is using drug that may affect rectal tone * Calcium Channel Blocker such as: * Nifedipine (Osmo-Ad…

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00972907